# South America Biobanking Market > South America Biobanking Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Applications (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations), By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.21% - **2024:** $ 7.5 Billion - **2025:** $ 7.82 Billion - **2035:** $ 11.8 Billion - **Key Players:** Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biobanking Solutions (FI), LGC Group (GB) **Report ID:** MRFR/MED/52638-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-biobanking-market-54401 --- ## Market Summary ## **South America Biobanking Market Overview** As per MRFR analysis, the South America Biobanking Market Size was estimated at 394.4 (USD Million) in 2023. The South America Biobanking Market Industry is expected to grow from 411.2(USD Million) in 2024 to 640 (USD Million) by 2035. The South America Biobanking Market CAGR (growth rate) is expected to be around 4.104% during the forecast period (2025 - 2035). **Key South America Biobanking Market Trends Highlighted** The South America Biobanking Market is seeing big changes because of progress in medical research and a growing interest in personalized therapy. As countries in the area improve their healthcare systems, more and more people are realizing how important biobanks are for research. Government programs that aim to improve research infrastructure and cooperation amongst universities are driving this momentum. Brazil's National Health Surveillance Agency has taken initiatives to regulate and encourage biobanking activities.  This makes sure that methods are ethical and consistent with worldwide standards. As both public and private organizations look for new ways to use biobanks, the South America Biobanking Market keeps growing. Researchers are still interested in biobanking for genetic studies and storing a wide range of biological samples, especially when it comes to investigating diseases that are common in the area. Because South American cultures are genetically diverse, the chance to look into unique health problems is a big reason why people invest in biobanking.  Also, as the area adopts new technologies, digital platforms for managing data and keeping track of samples are becoming important tools for improving biobank operations. Recent trends show that more people are aware of how biobanks might help improve healthcare. This shows how important it is for biobanking processes to be open and easy to understand.Community involvement projects are becoming a big element of the biobanking process.  They help people trust the process and get involved. This tendency helps in collecting samples and makes the ethical framework that biobanks work under even better. Overall, the South America Biobanking Market is changing quickly because of these changes and a dedication to improving health outcomes through research and new ideas. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Biobanking Market Drivers** **Increasing Demand for Personalized Medicine** The rising trend toward personalized medicine in South America is a significant driver for the South America Biobanking Market Industry. As healthcare becomes increasingly tailored to individual patient profiles, the need for biobanks that can supply genetic, blood, and other biological samples is escalating. According to the South American Health Organization, personalized medicine practices in Brazil have seen growth rates exceeding 20% annually, reflecting a commons-based shift toward utilizing biobanking resources for more effective treatments. Major players in the biobanking arena, such as the Brazilian Biosciences National Laboratory and the National Institute of Cancer in Argentina, are enhancing capabilities and fostering collaboration to meet this demand. This shift is pivotal in supporting the need for biobanking facilities that can provide the necessary resources for innovative therapies tailored to individual genetic makeups. **Growing Research and Development Activities** The South America Biobanking Market Industry is significantly driven by an increase in Research and Development (R&D) activities across the region, underpinned by governmental funding and initiatives. Governments in countries like Brazil and Argentina have allocated substantial budgets toward biomedical research.  For instance, Brazil is expected to spend over 6% of its GDP on healthcare and R&D activities, which can lead to higher demands for biobanked samples used in clinical trials and studies.In collaboration with major universities, such as the University of So Paulo and National University of La Plata, the focus on sustainable practices and innovation aligns with the biobanking industry, positioning it as a key contributor to future advancements in medical research. **Increased Incidence of Chronic Diseases** The rising incidence of chronic diseases is another critical driver for the South America Biobanking Market Industry. Chronic diseases, such as diabetes and cancer, are projected to affect over 50% of the adult population in South America by 2035, according to the Pan American Health Organization.  This has necessitated extensive biobanking efforts to facilitate research in disease prevention, understanding genetic predispositions, and developing new treatments.Institutions like the Brazilian Cancer Institute and the Argentine Society of Diabetology are investing in biobanked resources to support ongoing studies, leading to a more informed approach in tackling these widespread health issues. **South America Biobanking Market Segment Insights** **Biobanking Market Sample Type Insights** The South America Biobanking Market is growing, especially in the Sample Type sector, which is important for supporting a wide range of biomedical research and development. Blood products make up a large part of this market and are very important for clinical research, diagnostics, and the development of new treatments. Blood products are important because they help with research in transfusion medicine and genetics. This drives demand and innovation in biobanking procedures in the area. Tissues are another important category that are very important for cancer research and regenerative medicine because they give us important information about how diseases work and how they might be treated. The preservation and study of tissues help create targeted medicines that are becoming more important in South American healthcare, which is driving market growth even more.  Cells make up a large part of the market and are necessary for stem cell research and therapeutic uses. They are also important for the growing field of customized medicine. As cellular therapies get more popular and biobanking methods become more important to make sure these samples stay viable and last a long time, this part becomes even more important.Nucleic acids are essential for molecular and genetic research, especially when it comes to understanding genetic abnormalities and infectious diseases. This is in line with regional healthcare efforts to improve disease prevention and management. To get correct study results, nucleic acids must be stored properly and quality controlled. This is good for the South America Biobanking Market dynamics.  Microbiome samples have become more popular as people learn more about how gut health affects overall health. The focus on the microbiome in this area shows how much more study is being done on how it affects different health concerns, which is getting people interested in the market. The Sample Type section shows that the South America Biobanking Market is becoming more diverse, meeting the needs of different types of research and healthcare. The way these parts work together shows that an ecosystem is growing, which is pushing for better use of resources and new technologies in biobanking rules and practices across South America. These new developments in the Sample Type segment show that the region is dedicated to improving biomedical research and healthcare solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Biobanking Market Application Insights** The Application segment of the South America Biobanking Market encompasses various crucial areas such as Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine, each playing a vital role in advancing healthcare and scientific innovation in the region. Research and Development has a predominant role as it fuels the discovery of new therapies and medical products, driving the need for reliable biological samples. Clinical Trials represent a significant component, as they rely heavily on biobanks to provide high-quality specimens necessary for trials, particularly for conditions prevalent in South America, which enhances localized medical research efforts. Personalized Medicine is gaining momentum as advancements in genomic technologies permit more tailored therapeutic approaches, relying on biobanked material to inform patient-specific treatments. Regenerative Medicine also emerges as an important area, focusing on restoring or replacing damaged tissues, heavily dependent on the availability of stem cells and bio-specimens from biobanks, increasingly becoming a priority due to its potential to address chronic diseases prevalent in the region. The overall dynamics of the South America Biobanking Market highlight an interdependence on these applications, facilitating significant opportunities for growth while addressing the diverse health needs of the population. **Biobanking Market End Use Insights** The South America Biobanking Market is significantly influenced by its End Use segmentation, comprising Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a vital role, leveraging biobanks for innovative studies that advance scientific knowledge and healthcare solutions. Biotechnology Companies are increasingly utilizing biobanks for drug development, aiming to enhance therapeutic efficiency and deliver personalized medicine.  Pharmaceutical Companies, on the other hand, depend on biobanking for extensive data and samples crucial for clinical trials and R&D initiatives, driving their product pipeline.Government Organizations also contribute significantly, often funding biobanking initiatives to support public health research and policy-making, ensuring that collective health concerns are addressed. The diverse applications across these segments underline the growing relevance of biobanking in fostering research collaborations, optimizing drug development, and promoting health advancements in the region. Overall, the interplay of these sectors within the South America Biobanking Market highlights the importance of biobanks in enhancing research capabilities and fostering innovation for health solutions in South American countries. **Biobanking Market Storage Type Insights** The Storage Type segment of the South America Biobanking Market plays a crucial role in preserving biological samples for research and future applications. Within this segment, Vapor Phase Storage is pivotal as it maintains samples at ultra-low temperatures, ensuring the integrity of sensitive biological materials, particularly in long-term storage scenarios. Liquid Phase Storage, on the other hand, also offers effective preservation techniques that cater to diverse sample requirements but is significantly utilized for short-term storage solutions. Cryopreservation Storage remains a dominant method for preserving cells, tissues, and organs, which is essential for both research and therapeutic applications. This segment is largely driven by increasing Research and Development activities focused on personalized medicine and regenerative therapies in South America. Moreover, government initiatives aimed at enhancing biobanking facilities contribute to growth, as they emphasize the need for advanced storage solutions. Overall, the varied methods of storage are instrumental in the evolving landscape of biobanking, enabling better sample management and accessibility across the region. **Biobanking Market Regional Insights** The South America Biobanking Market has a strong structure that is backed by different factors in each region. Brazil is the leader in this market because it has a lot of research facilities and makes big expenditures in biobanking facilities that meet the needs of both local and international researchers. Mexico is next, focusing on building biobanks that help with clinical research and new treatments, which shows its strategic role in the healthcare field. Argentina also plays a big part, with projects that focus on bio preservation and gathering biological resources, making its contributions to biobanking efforts in both the region and the world even bigger. The rest of South America is gaining ground, with more government support and cooperation across countries aimed at creating a united approach to biobanking procedures, which will make the industry as a whole more powerful. The South America Biobanking Market has a lot of room to grow because biobanking is being used in more and more ways in these areas, such as personalized medicine and biotechnology advances. This shows how important it is for regions to contribute to global health research and clinical advancements. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Biobanking Market Key Players and Competitive Insights** The South America Biobanking Market has grown and changed a lot in the last few years. This is because more biomedical research is being done and more attention is being paid to personalized treatment. There are both big global corporations and smaller regional companies in the competitive environment. They are all trying to use new technologies and creative ways to gather, store, and analyse samples. Biobanking involves a wide range of people and organizations, such as universities, healthcare providers, and pharmaceutical businesses. This makes for a diversified ecosystem. As the need for biological samples for research and medical purposes grows, companies in the industry are working to stay ahead of the competition by improving their services, making their operations more efficient, and developing strategic partnerships.  Evotec is a major player in the South America Biobanking Market because it has a lot of experience in drug discovery and development and can provide biobanking solutions that meet the needs of healthcare projects in the area. The organization has built a strong reputation by offering a full range of biobanking services, such as making sure they follow the rules, managing data, and processing samples of high quality. Evotec is a trustworthy partner for research institutes and pharmaceutical firms that want to do personalized medicine studies and clinical trials because it takes an integrated approach to biobanking that combines innovative technology with scientific knowledge. The company's commitment to innovation and quality ensures stakeholders of dependable sample management systems, creating relationships that increase its competitive standing in the biobanking landscape of South America.  Natera is another important company in the South America Biobanking Market. It is known for its cutting-edge genetic testing and diagnostic services. The company focuses on non-invasive prenatal diagnostics and oncology, which is in line with the growing need for tailored healthcare in the area. Natera's capabilities come from its core technology skills and its dedication to providing high-value services like DNA analysis and sample storage. Its strong position in the market is backed up by partnerships with health systems and research institutes, which makes biobanking services available to more people.  Natera has also made smart mergers and acquisitions that improve its skills and increase its presence in South America, allowing it to get deeper into the market and improve its product range. Natera is still a leader in innovation in the biobanking market since it focuses on research and development to meet the changing needs of healthcare in South America. **Key Companies in the South America Biobanking Market Include:** - Evotec - Natera - Biospecimen Solutions - Roche - Biobank - Lifebank - Biobanco de Células - Celsus - Merck KGaA - CryoCell International - AstraZeneca - Bioscientia - Banco de Células - Thermo Fisher Scientific **South America Biobanking Market Industry Developments** Recent developments in the South America Biobanking Market have been marked by significant growth and increased investments in biobanking facilities. The region has seen advancements in technology, particularly in cellular preservation and genetic testing services. Companies such as Evotec and Natera have expanded their operations, focusing on collaborations aimed at enhancing personalized medicine. In September 2023, Roche announced a strategic partnership with local biobanks to improve access to genomic data, which supports ongoing research initiatives.  Additionally, in August 2023, a merger between Lifebank and Biobank was finalized, consolidating their resources and expanding their specimen collection capabilities across Brazil.The market valuation for companies such as Thermo Fisher Scientific, Merck KGaA, and AstraZeneca has shown promising increases, largely due to heightened demand for biobanking services amid a growing emphasis on precision medicine in South America.  Moreover, major happenings over the past couple of years include the establishment of new biobank networks aimed at enhancing research collaboration, with notable projects launched in countries like Argentina and Brazil in early 2022, reflecting the region's commitment to advancing healthcare and disease research through comprehensive biobanking initiatives. **South America Biobanking Market Segmentation Insights** **Biobanking Market Sample Type Outlook** - Blood Products - Tissues - Cells - Nucleic Acids - Microbiome Samples **Biobanking Market Application Outlook** - Research and Development - Clinical Trials - Personalized Medicine - Regenerative Medicine **Biobanking Market End Use Outlook** - Academic Research Institutions - Biotechnology Companies - Pharmaceutical Companies - Government Organizations **Biobanking Market Storage Type Outlook** - Vapor Phase Storage - Liquid Phase Storage - Cryopreservation Storage **Biobanking Market Regional Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Market Drivers ### Rising Awareness of Genetic Research The rising awareness of genetic research among the South American population is significantly impacting the biobanking market. As individuals become more informed about the importance of genetic testing and personalized medicine, there is a growing willingness to participate in biobanking initiatives. This trend is particularly evident in urban areas, where educational campaigns and outreach programs have successfully increased public engagement. In 2025, it is estimated that participation rates in biobanking studies could rise by 15%, driven by enhanced public understanding of the benefits of biobanking for health outcomes. This increased participation not only enriches the diversity of biological samples available but also supports the development of tailored medical treatments. Consequently, the heightened awareness of genetic research is likely to play a crucial role in the expansion of the biobanking market in South America. ### Growing Demand for Biobanking Services The increasing demand for biobanking services in South America is driven by the rising need for personalized medicine and advanced research. As healthcare systems evolve, there is a notable shift towards precision medicine, which relies heavily on biobanked samples. The biobanking market in South America is projected to grow at a CAGR of approximately 8% from 2025 to 2030. This growth is fueled by the need for high-quality biological samples for research and clinical trials, which are essential for developing targeted therapies. Furthermore, the expansion of biobanks in academic and research institutions enhances the availability of diverse biological materials, thereby supporting innovative research initiatives. As a result, the demand for biobanking services is expected to continue its upward trajectory, reflecting the critical role of biobanks in advancing medical research and healthcare solutions. ### Investment in Research and Development Investment in research and development (R&D) within the biobanking market is a significant driver of growth in South America. Governments and private entities are increasingly allocating funds to enhance biobanking infrastructure and capabilities. For instance, the Brazilian government has initiated several funding programs aimed at supporting biobanking initiatives, which are crucial for advancing scientific research. In 2025, it is estimated that R&D spending in the biobanking sector could reach approximately $200 million, reflecting a growing recognition of the importance of biobanks in medical research. This investment not only facilitates the establishment of new biobanks but also improves existing facilities, ensuring they meet international standards. Consequently, the enhanced R&D environment is likely to attract more researchers and institutions to utilize biobanking services, further propelling the market forward. ### Collaboration Between Public and Private Sectors Collaboration between public and private sectors is emerging as a vital driver for the biobanking market in South America. Partnerships between government agencies, academic institutions, and private companies are fostering innovation and resource sharing. Such collaborations often lead to the establishment of biobanks that are better equipped to meet the needs of researchers and healthcare providers. For example, joint ventures can result in the pooling of financial resources, expertise, and biological samples, enhancing the overall efficiency of biobanking operations. In 2025, it is anticipated that collaborative initiatives could account for nearly 30% of new biobanking projects in the region. This synergy not only accelerates research but also ensures that biobanks are aligned with the latest scientific advancements, ultimately benefiting the healthcare landscape in South America. ### Technological Integration in Biobanking Operations Technological integration in biobanking operations is a key driver for the biobanking market in South America. The adoption of advanced technologies such as automation, data management systems, and biobanking software is enhancing the efficiency and reliability of biobanking processes. In 2025, it is projected that nearly 40% of biobanks in the region will implement automated systems to streamline sample processing and storage. This technological advancement not only reduces human error but also improves sample tracking and data management, which are critical for research integrity. Furthermore, the integration of digital platforms facilitates better collaboration among researchers, enabling them to access and share biobanked samples more effectively. As a result, the ongoing technological evolution is expected to significantly contribute to the growth and sustainability of the biobanking market in South America. ## Future Outlook The [Biobanking Market](https://www.marketresearchfuture.com/reports/biobanking-market-5967) in South America is projected to grow at a 4.21% CAGR from 2025 to 2035, driven by advancements in personalized medicine, regulatory support, and increasing research funding. **New opportunities:** - Expansion of biorepository services for rare diseases - Development of mobile biobanking units for remote areas - Partnerships with pharmaceutical companies for clinical trials By 2035, the biobanking market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Sample Type: Blood Products (Largest) vs. Nucleic Acids (Fastest-Growing) In the South America biobanking market, the distribution of market share among sample types reveals that Blood Products currently hold the largest share, demonstrating strong demand driven by clinical research and diagnostics needs. Following Blood Products, Tissues and Cells also play significant roles, while Nucleic Acids and Microbiome Samples represent emerging categories with increasing relevance in personalized medicine and biotechnology application. Growth trends in the sample type segment are heavily influenced by advancements in genomics and proteomics, leading to a surge in Nucleic Acids as the fastest-growing segment. The rise in biobanking facilities, along with collaborations between research institutes and biopharma companies, is fueling the demand for all sample types, especially as personalized medicine and precision therapies gain traction in the region. Blood Products (Dominant) vs. Nucleic Acids (Emerging) Blood Products dominate the South America biobanking market due to their extensive use in transfusions and bioprocessing, benefiting from a well-established regulatory framework and a consistent supply chain. In contrast, Nucleic Acids are emerging rapidly, spurred by innovations in biotechnological applications and increasing investments in genetic research. The demand for precision diagnostics and targeted therapies is contributing to the accelerating growth of Nucleic Acids, making them vital for future biobanking initiatives. Both segments showcase unique characteristics—Blood Products emphasize traditional medical needs, while Nucleic Acids represent the cutting edge of genomic research, highlighting a dynamic interplay in the evolving landscape of biobanking. ### By Application: Research and Development (Largest) vs. Clinical Trials (Fastest-Growing) The biobanking market segment in South America is predominantly driven by Research and Development, which accounts for the largest share due to its critical role in advancing scientific inquiries and medical advancements. Clinical Trials have emerged as a vital component, rapidly gaining traction as new therapies are developed and tested, indicating a healthy distribution among these segments. Growth in the Application segment is primarily fueled by increasing investments in biotechnology and a growing focus on personalized medicine. The demand for innovative healthcare solutions, coupled with an emphasis on Regenerative Medicine, further drives the need for biobanking services. These trends signify an evolving landscape where Research and Development remain foundational while Clinical Trials are set to expand significantly in the coming years. Research and Development: Dominant vs. Clinical Trials: Emerging Research and Development is the dominant application in the biobanking sector, playing a crucial role in understanding diseases and developing new therapeutic strategies. Its comprehensive approach to collecting, processing, and storing biological samples makes it essential for cutting-edge research. Clinical Trials, on the other hand, are emerging rapidly as a vital application due to the increasing need for clinical validation of new drugs and treatments. The intersection of these two segments is crucial, as Research and Development provides the foundational knowledge needed for effective Clinical Trials, thereby creating a symbiotic relationship that supports innovation in the biobanking field. ### By End-use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing) In the South America biobanking market, Pharmaceutical Companies hold the largest share, dominating the landscape with their extensive need for biobanked samples for drug development and clinical trials. Academic Research Institutions and Government Organizations also play a significant role, but their market shares are comparatively lower, reflecting the specialized focus of Pharmaceutical Companies in high-stakes research and development activities. Growth trends in this segment are largely driven by increasing investments in healthcare and the rising demand for advanced therapies. Biotechnology Companies are emerging rapidly as they leverage biobanks for innovative research, positioning themselves for lucrative collaboration opportunities with larger pharmaceutical firms. This synergy is expected to fuel significant growth in the biobanking sector across South America, showcasing the dynamic interplay between established and emerging players. Academic Research Institutions (Dominant) vs. Government Organizations (Emerging) Academic Research Institutions are essential players in the biobanking market, providing critical contributions to scientific knowledge and medical advancements. They often utilize biobanks for large-scale studies and collaborative research, tapping into diverse biological samples that aid in various research fields. On the other hand, Government Organizations are seeing an increase in their relevance as emerging entities, focusing on public health initiatives and regulatory research. Their involvement is pivotal for the establishment of biobanking standards and practices, encouraging transparency and accessibility of biological data, thus fostering trust and collaboration among stakeholders. As Government Organizations continue to evolve, their role in enhancing biobanking strategies is likely to become more pronounced, making them key players in the sector. ### By Storage Type: Vapor Phase Storage (Largest) vs. Liquid Phase Storage (Fastest-Growing) The market share distribution in the 'Storage Type' segment shows that Vapor Phase Storage holds a dominant position, preferred for its efficiency in long-term biological sample preservation. In comparison, Liquid Phase Storage is emerging rapidly, gaining attention for its ability to provide immediate access to samples and be suitable for various cellular materials, thus diversifying storage capabilities. Growth trends indicate a shift towards Liquid Phase Storage, driven by increasing demand for biobanks to adopt versatile storage solutions and advancements in cryogenic technologies. The need for quick retrieval and sample integrity has propelled this segment's growth as institutions strive for improved sample management and research throughput, making it a key player in the evolving landscape of biobanking. Storage: Vapor Phase (Dominant) vs. Liquid Phase (Emerging) Vapor Phase Storage is recognized for its superior temperature stability and sample protection, making it the preferred choice among biobanks for preserving sensitive biological specimens. This method utilizes vapor from liquid nitrogen to maintain conditions ideal for long-term storage. Conversely, Liquid Phase Storage is gaining traction due to its flexibility and rapid sample access capabilities, essential for contemporary research needs. As biobanks look to enhance operational efficiencies and ensure sample viability, these two storage types are defining the future of biobanking practices in the region. ## Regional Market Share Analysis ### Brazil : Strong Demand and Infrastructure Development Key markets include São Paulo, Rio de Janeiro, and Minas Gerais, where major research institutions and universities are located. The competitive landscape features significant players like Thermo Fisher Scientific and Qiagen, which have established a strong presence. Local dynamics are characterized by collaborations between public and private sectors, fostering innovation. The biobanking sector is increasingly applied in clinical research, drug development, and regenerative medicine, making Brazil a hub for biobanking activities. ### Mexico : Growing Investment and Research Focus Key markets include Mexico City and Guadalajara, where several research institutions are located. The competitive landscape features players like Illumina and Merck KGaA, which are expanding their operations in the region. Local market dynamics are influenced by partnerships between academic institutions and private companies, fostering innovation. The biobanking sector is increasingly utilized in clinical trials and public health research, positioning Mexico as a growing player in the biobanking market. ### Argentina : Focus on Research and Development Key markets include Buenos Aires and Córdoba, where major universities and research centers are located. The competitive landscape features companies like STEMCELL Technologies and BioLife Sciences, which are establishing a presence in the region. Local dynamics are characterized by collaborations between public institutions and private enterprises, promoting innovation. The biobanking sector is increasingly applied in clinical research and drug development, making Argentina a vital player in the South American market. ### Rest of South America : Regional Growth and Collaboration Key markets include countries like Chile, Colombia, and Peru, where research institutions are expanding. The competitive landscape features a mix of local and international players, including LGC Group and ReproCELL, which are establishing operations in these markets. Local dynamics are influenced by collaborations between governments and private sectors, fostering innovation. The biobanking sector is increasingly utilized in public health initiatives and research, positioning the region for future growth. ## Competitive Benchmarking The biobanking market in South America is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine, advancements in genomics, and a growing emphasis on research and development. Key players such as Thermo Fisher Scientific (US), Qiagen (DE), and Illumina (US) are strategically positioned to leverage these trends. Thermo Fisher Scientific (US) focuses on innovation through its extensive portfolio of biobanking solutions, while Qiagen (DE) emphasizes partnerships to enhance its technological capabilities. Illumina (US) is heavily invested in genomic sequencing technologies, which positions it favorably in the evolving market. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and collaborative efforts. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to emerge, while larger companies consolidate their market positions through strategic acquisitions and partnerships. In October 2025, Thermo Fisher Scientific (US) announced a partnership with a leading South American university to establish a biobank dedicated to rare diseases. This initiative not only enhances their local presence but also aligns with their strategy to support research in underrepresented areas. The partnership is expected to facilitate access to critical biological samples, thereby strengthening their market position. In September 2025, Qiagen (DE) launched a new line of biobanking kits specifically designed for the South American market, tailored to meet local regulatory requirements. This move indicates a strategic focus on regional customization, which is likely to enhance customer satisfaction and expand their market share. By addressing local needs, Qiagen positions itself as a responsive and adaptable player in the biobanking sector. In August 2025, Illumina (US) expanded its operations in Brazil by opening a new facility aimed at increasing its production capacity for genomic sequencing products. This expansion reflects a commitment to meeting the growing demand for genomic research in the region. The facility is expected to enhance supply chain reliability and reduce lead times for customers, thereby solidifying Illumina's competitive edge. As of November 2025, current trends in the biobanking market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in research processes. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and sustainable practices. This shift suggests that companies that prioritize these areas will be better positioned to thrive in the future. ## Recent News & Developments Recent developments in the South America Biobanking Market have been marked by significant growth and increased investments in biobanking facilities. The region has seen advancements in technology, particularly in cellular preservation and genetic testing services. Companies such as Evotec and Natera have expanded their operations, focusing on collaborations aimed at enhancing personalized medicine. In September 2023, Roche announced a strategic partnership with local biobanks to improve access to genomic data, which supports ongoing research initiatives.  Additionally, in August 2023, a merger between Lifebank and Biobank was finalized, consolidating their resources and expanding their specimen collection capabilities across Brazil.The market valuation for companies such as Thermo Fisher Scientific, Merck KGaA, and AstraZeneca has shown promising increases, largely due to heightened demand for biobanking services amid a growing emphasis on precision medicine in South America.  Moreover, major happenings over the past couple of years include the establishment of new biobank networks aimed at enhancing research collaboration, with notable projects launched in countries like Argentina and Brazil in early 2022, reflecting the region's commitment to advancing healthcare and disease research through comprehensive biobanking initiatives. ## Report Scope | MARKET SIZE 2024 | 7.5(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.82(USD Billion) | | MARKET SIZE 2035 | 11.8(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.21% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biobanking Solutions (FI), LGC Group (GB) | | Segments Covered | Sample Type, Application, End-use, Storage Type | | Key Market Opportunities | Emerging technologies in biobanking enhance personalized medicine and drive demand for innovative storage solutions. | | Key Market Dynamics | Growing demand for personalized medicine drives biobanking advancements and regulatory adaptations in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the current valuation of the biobanking market in South America?** A: The biobanking market in South America was valued at $7.5 Billion in 2024. **Q: What is the projected market size for biobanking in South America by 2035?** A: The market is projected to reach $11.8 Billion by 2035. **Q: What is the expected CAGR for the South America biobanking market from 2025 to 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 4.21%. **Q: Which companies are leading the biobanking market in South America?** A: Key players include Thermo Fisher Scientific, Qiagen, Illumina, and Merck KGaA. **Q: What are the main sample types in the South America biobanking market?** A: Main sample types include Blood Products, Tissues, Cells, Nucleic Acids, and Microbiome Samples. **Q: How much is the Blood Products segment expected to grow by 2035?** A: The Blood Products segment is projected to grow from $1.5 Billion to $2.4 Billion by 2035. **Q: What applications are driving the biobanking market in South America?** A: Applications include Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine. **Q: What is the expected growth for the Pharmaceutical Companies segment by 2035?** A: The Pharmaceutical Companies segment is expected to grow from $2.5 Billion to $4.0 Billion by 2035. **Q: What storage types are utilized in the biobanking market?** A: Storage types include Vapor Phase Storage, Liquid Phase Storage, and Cryopreservation Storage. **Q: How is the Cryopreservation Storage segment expected to perform by 2035?** A: The Cryopreservation Storage segment is projected to increase from $3.0 Billion to $4.8 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-biobanking-market-54401*